Top

Published in:

Open Access 01-12-2015 | Review

Drugging the unfolded protein response in acute leukemias

Authors: Behzad Kharabi Masouleh, Eric Chevet, Jens Panse, Edgar Jost, Michael O’Dwyer, Tim H. Bruemmendorf, Afshin Samali

Published in: Journal of Hematology & Oncology | Issue 1/2015

Abstract

The unfolded protein response (UPR), an endoplasmic reticulum (ER) stress-induced signaling cascade, is mediated by three major stress sensors IRE-1α, PERK, and ATF6α. Studies described the UPR as a critical network in selection, adaptation, and survival of cancer cells. While previous reviews focused mainly on solid cancer cells, in this review, we summarize the recent findings focusing on acute leukemias. We take into account the impact of the underlying genetic alterations of acute leukemia cells, the leukemia stem cell pool, and provide an outline on the current genetic, clinical, and therapeutic findings. Furthermore, we shed light on the important oncogene-specific regulation of individual UPR signaling branches and the therapeutic relevance of this information to answer the question if the UPR could be an attractive novel target in acute leukemias.

Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13(2):89–102. doi:10.1038/nrm3270.PubMed

Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. Endoplasmic reticulum stress in malignancy. Cancer Cell. 2014;25(5):563–73. doi:10.1016/j.ccr.2014.03.015.PubMedCrossRef

Chambers JE, Marciniak SJ. Cellular mechanisms of endoplasmic reticulum stress signaling in health and disease. 2. Protein misfolding and ER stress. Am J Physiol Cell Physiol. 2014;307(8):C657–70. doi:10.1152/ajpcell.00183.2014.PubMedCrossRef

Gorman AM, Healy SJ, Jager R, Samali A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther. 2012;134(3):306–16. doi:10.1016/j.pharmthera.2012.02.003.PubMedCrossRef

Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833(12):3460–70. doi:10.1016/j.bbamcr.2013.06.028.PubMedCrossRef

Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov. 2015;5(6):586–97. doi:10.1158/2159-8290.CD-14-1490.PubMedCrossRef

Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol. 2000;2(6):326–32. doi:10.1038/35014014.PubMedCrossRef

Shamu CE, Walter P. Oligomerization and phosphorylation of the Ire1p kinase during intracellular signaling from the endoplasmic reticulum to the nucleus. EMBO J. 1996;15(12):3028–39.PubMedCentralPubMed

Scheuner D, Song B, McEwen E, Liu C, Laybutt R, Gillespie P, et al. Translational control is required for the unfolded protein response and in vivo glucose homeostasis. Mol Cell. 2001;7(6):1165–76.PubMedCrossRef

10.

Rzymski T, Milani M, Singleton DC, Harris AL. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle. 2009;8(23):3838–47.PubMedCrossRef

11.

Ye J, Koumenis C. ATF4, an ER stress and hypoxia-inducible transcription factor and its potential role in hypoxia tolerance and tumorigenesis. Curr Mol Med. 2009;9(4):411–6.PubMedCrossRef

12.

Ameri K, Harris AL. Activating transcription factor 4. Int J Biochem Cell Biol. 2008;40(1):14–21. doi:10.1016/j.biocel.2007.01.020.PubMedCrossRef

13.

Wek RC, Anthony TG. EXtENDINg beta cell survival by UPRegulating ATF4 translation. Cell Metab. 2006;4(5):333–4. doi:10.1016/j.cmet.2006.10.006.PubMedCrossRef

14.

Cullinan SB, Diehl JA. PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress. J Biol Chem. 2004;279(19):20108–17. doi:10.1074/jbc.M314219200.PubMedCrossRef

15.

Shen J, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell. 2002;3(1):99–111.PubMedCrossRef

16.

Ye J, Rawson RB, Komuro R, Chen X, Dave UP, Prywes R, et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. Mol Cell. 2000;6(6):1355–64.PubMedCrossRef

17.

Brodsky JL, Skach WR. Protein folding and quality control in the endoplasmic reticulum: recent lessons from yeast and mammalian cell systems. Curr Opin Cell Biol. 2011;23(4):464–75. doi:10.1016/j.ceb.2011.05.004.PubMedCentralPubMedCrossRef

18.

Uemura A, Oku M, Mori K, Yoshida H. Unconventional splicing of XBP1 mRNA occurs in the cytoplasm during the mammalian unfolded protein response. J Cell Sci. 2009;122(Pt 16):2877–86. doi:10.1242/jcs.040584.PubMedCrossRef

19.

Jurkin J, Henkel T, Nielsen AF, Minnich M, Popow J, Kaufmann T, et al. The mammalian tRNA ligase complex mediates splicing of XBP1 mRNA and controls antibody secretion in plasma cells. EMBO J. 2014;33(24):2922–36. doi:10.15252/embj.201490332.PubMedCrossRef

20.

Lu Y, Liang FX, Wang X. A synthetic biology approach identifies the mammalian UPR RNA ligase RtcB. Mol Cell. 2014;55(5):758–70. doi:10.1016/j.molcel.2014.06.032.PubMedCrossRef

21.

Kosmaczewski SG, Edwards TJ, Han SM, Eckwahl MJ, Meyer BI, Peach S, et al. The RtcB RNA ligase is an essential component of the metazoan unfolded protein response. EMBO Rep. 2014;15(12):1278–85. doi:10.15252/embr.201439531.PubMedCrossRef

22.

Ray A, Zhang S, Rentas C, Caldwell KA, Caldwell GA. RTCB-1 mediates neuroprotection via XBP-1 mRNA splicing in the unfolded protein response pathway. J Neurosci. 2014;34(48):16076–85. doi:10.1523/JNEUROSCI.1945-14.2014.PubMedCentralPubMedCrossRef

23.

Acosta-Alvear D, Zhou Y, Blais A, Tsikitis M, Lents NH, Arias C, et al. XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell. 2007;27(1):53–66. doi:10.1016/j.molcel.2007.06.011.PubMedCrossRef

24.

Lee K, Tirasophon W, Shen X, Michalak M, Prywes R, Okada T, et al. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev. 2002;16(4):452–66. doi:10.1101/gad.964702.PubMedCentralPubMedCrossRef

25.

Maurel M, Chevet E, Tavernier J, Gerlo S. Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem Sci. 2014;39(5):245–54. doi:10.1016/j.tibs.2014.02.008.PubMedCrossRef

26.

Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014;14(9):581–97. doi:10.1038/nrc3800.PubMedCrossRef

27.

Yadav RK, Chae SW, Kim HR, Chae HJ. Endoplasmic reticulum stress and cancer. J Cancer Prevention. 2014;19(2):75–88. doi:10.15430/JCP.2014.19.2.75.PubMedCrossRef

28.

Hetz C, Chevet E. Theme series—UPR in cancer. Semin Cancer Biol. 2015. doi:10.1016/j.semcancer.2015.04.008.

29.

Dejeans N, Barroso K, Fernandez-Zapico ME, Samali A, Chevet E. Novel roles of the unfolded protein response in the control of tumor development and aggressiveness. Semin Cancer Biol. 2015. doi:10.1016/j.semcancer.2015.04.007.

30.

Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood. 2013;121(18):3563–72. doi:10.1182/blood-2013-01-451781.PubMedCentralPubMedCrossRef

31.

Conway O’Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014;2014:103175. doi:10.1155/2014/103175.PubMedCentralPubMedCrossRef

32.

Eriksson A, Lennartsson A, Lehmann S. Epigenetic aberrations in acute myeloid leukemia: early key events during leukemogenesis. Exp Hematol. 2015. doi:10.1016/j.exphem.2015.05.009.

33.

Lamba G, Zaidi SK, Luebbers K, Verschraegen C, Stein GS, Rosmarin A. Epigenetic landscape of acute myelogenous leukemia—moving toward personalized medicine. J Cell Biochem. 2014;115(10):1669–72. doi:10.1002/jcb.24853.PubMedCrossRef

34.

Mazzarella L, Riva L, Luzi L, Ronchini C, Pelicci PG. The genomic and epigenomic landscapes of AML. Semin Hematol. 2014;51(4):259–72. doi:10.1053/j.seminhematol.2014.08.007.PubMedCrossRef

35.

Gutierrez SE, Romero-Oliva FA. Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol. 2013;6:57. doi:10.1186/1756-8722-6-57.PubMedCentralPubMedCrossRef

36.

Hatlen MA, Wang L, Nimer SD. AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front Med. 2012;6(3):248–62. doi:10.1007/s11684-012-0206-6.PubMedCrossRef

37.

Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2014;27(1):3–9. doi:10.1016/j.beha.2014.04.006.PubMedCrossRef

38.

Sakamoto KM, Grant S, Saleiro D, Crispino JD, Hijiya N, Giles F, et al. Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab. 2015;114(3):397–402. doi:10.1016/j.ymgme.2014.11.017.PubMedCrossRef

39.

Roboz GJ. Current treatment of acute myeloid leukemia. Curr Opin Oncol. 2012;24(6):711–9. doi:10.1097/CCO.0b013e328358f62d.PubMedCrossRef

40.

Friedman AD, Keefer JR, Kummalue T, Liu H, Wang QF, Cleaves R. Regulation of granulocyte and monocyte differentiation by CCAAT/enhancer binding protein alpha. Blood Cells Mol Dis. 2003;31(3):338–41.PubMedCrossRef

41.

Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer. 2004;4(5):394–400. doi:10.1038/nrc1363.PubMedCrossRef

42.

Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3):263–70. doi:10.1038/85820.PubMedCrossRef

43.

Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program. 2013;2013:220–6. doi:10.1182/asheducation-2013.1.220.PubMedCrossRef

44.

De Braekeleer E, Douet-Guilbert N, De Braekeleer M. RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol. 2014;7(3):347–57. doi:10.1586/17474086.2014.903794.PubMedCrossRef

45.

Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586–95. doi:10.1200/JCO.2009.22.9088.PubMedCrossRef

46.

DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia. Expert Opin Pharmacother. 2015;16(1):95–106. doi:10.1517/14656566.2015.981527.PubMedCrossRef

47.

Montalban-Bravo G, Garcia-Manero G. Novel drugs for older patients with acute myeloid leukemia. Leukemia. 2015;29(4):760–9. doi:10.1038/leu.2014.244.PubMedCrossRef

48.

Erba HP. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res. 2015;39(2):183–91. doi:10.1016/j.leukres.2014.11.027.PubMedCrossRef

49.

Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–59. doi:10.1056/NEJMoa0904544.PubMedCrossRef

50.

Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29(4):770–5. doi:10.1038/leu.2014.216.PubMedCrossRef

51.

Schardt JA, Mueller BU, Pabst T. Activation of the unfolded protein response in human acute myeloid leukemia. Methods Enzymol. 2011;489:227–43. doi:10.1016/B978-0-12-385116-1.00013-3.PubMedCrossRef

52.

Schardt JA, Weber D, Eyholzer M, Mueller BU, Pabst T. Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res. 2009;15(11):3834–41. doi:10.1158/1078-0432.CCR-08-2870.PubMedCrossRef

53.

Schardt JA, Eyholzer M, Timchenko NA, Mueller BU, Pabst T. Unfolded protein response suppresses CEBPA by induction of calreticulin in acute myeloid leukaemia. J Cell Mol Med. 2010;14(6B):1509–19. doi:10.1111/j.1582-4934.2009.00870.x.PubMedCentralPubMedCrossRef

54.

Haefliger S, Klebig C, Schaubitzer K, Schardt J, Timchenko N, Mueller BU, et al. Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML. Blood. 2011;117(22):5931–40. doi:10.1182/blood-2010-08-304485.PubMedCentralPubMedCrossRef

55.

Collins SJ. Retinoic acid receptors, hematopoiesis and leukemogenesis. Curr Opin Hematol. 2008;15(4):346–51. doi:10.1097/MOH.0b013e3283007edf.PubMedCrossRef

56.

Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, et al. Acute promyelocytic leukemia: from genetics to treatment. Blood. 1994;83(1):10–25.PubMed

57.

Lonard DM, Lanz RB, O’Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev. 2007;28(5):575–87. doi:10.1210/er.2007-0012.PubMedCrossRef

58.

Loinder K, Soderstrom M. Functional analyses of an LXXLL motif in nuclear receptor corepressor (N-CoR). J Steroid Biochem Mol Biol. 2004;91(4–5):191–6. doi:10.1016/j.jsbmb.2004.04.006.PubMedCrossRef

59.

Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, Torchia J, et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature. 1997;387(6628):43–8. doi:10.1038/387043a0.PubMedCrossRef

60.

Khan MM, Nomura T, Kim H, Kaul SC, Wadhwa R, Shinagawa T, et al. Role of PML and PML-RARalpha in Mad-mediated transcriptional repression. Mol Cell. 2001;7(6):1233–43.PubMedCrossRef

61.

Khan MM, Nomura T, Chiba T, Tanaka K, Yoshida H, Mori K, et al. The fusion oncoprotein PML-RARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. J Biol Chem. 2004;279(12):11814–24. doi:10.1074/jbc.M312121200.PubMedCrossRef

62.

Greim H, Kaden DA, Larson RA, Palermo CM, Rice JM, Ross D, et al. The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment. Ann N Y Acad Sci. 2014;1310:7–31. doi:10.1111/nyas.12362.PubMedCentralPubMedCrossRef

63.

Kaelin Jr WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402. doi:10.1016/j.molcel.2008.04.009.PubMedCrossRef

64.

Coltella N, Percio S, Valsecchi R, Cuttano R, Guarnerio J, Ponzoni M, et al. HIF factors cooperate with PML-RARalpha to promote acute promyelocytic leukemia progression and relapse. EMBO Mol Med. 2014;6(5):640–50. doi:10.1002/emmm.201303065.PubMedCentralPubMed

65.

Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P, et al. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res. 2011;35(5):579–84. doi:10.1016/j.leukres.2010.10.020.PubMedCrossRef

66.

Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia—analysis of 848 patients. Leukemia. 2001;15(6):903–9.PubMedCrossRef

67.

Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102(2):462–9. doi:10.1182/blood-2002-11-3527.PubMedCrossRef

68.

Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8(11):851–64. doi:10.1038/nrc2501.PubMedCrossRef

69.

Rouault-Pierre K, Lopez-Onieva L, Foster K, Anjos-Afonso F, Lamrissi-Garcia I, Serrano-Sanchez M, et al. HIF-2alpha protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress. Cell Stem Cell. 2013;13(5):549–63. doi:10.1016/j.stem.2013.08.011.PubMedCrossRef

70.

Kuwabara WM, Zhang L, Schuiki I, Curi R, Volchuk A, Alba-Loureiro TC. NADPH oxidase-dependent production of reactive oxygen species induces endoplasmatic reticulum stress in neutrophil-like HL60 cells. PLoS One. 2015;10(2):e0116410. doi:10.1371/journal.pone.0116410.PubMedCentralPubMedCrossRef

71.

Ilaria RL, Jr. Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology Am Soc Hematol Educ Program. 2005:188–94. doi:10.1182/asheducation-2005.1.188.

72.

de Boer J, Walf-Vorderwulbecke V, Williams O. In focus: MLL-rearranged leukemia. Leukemia. 2013;27(6):1224–8. doi:10.1038/leu.2013.78.PubMedCrossRef

73.

Bernt KM, Hunger SP. Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia. Front Oncol. 2014;4:54. doi:10.3389/fonc.2014.00054.PubMedCentralPubMedCrossRef

74.

Hunger SP, Mullighan CG. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood. 2015;125(26):3977–87. doi:10.1182/blood-2015-02-580043.PubMedCrossRef

75.

Woo JS, Alberti MO, Tirado CA. Childhood B-acute lymphoblastic leukemia: a genetic update. Exp Hematol Oncol. 2014;3:16. doi:10.1186/2162-3619-3-16.PubMedCentralPubMedCrossRef

76.

Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet. 2013;45(3):242–52. doi:10.1038/ng.2532.PubMedCentralPubMedCrossRef

77.

Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–15. doi:10.1056/NEJMoa1403088.PubMedCentralPubMedCrossRef

78.

McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011;226(11):2762–81. doi:10.1002/jcp.22647.PubMedCrossRef

79.

Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420–30. doi:10.1182/blood-2014-04-531871.PubMedCentralPubMedCrossRef

80.

Knight T, Irving JA. Ras/Raf/MEK/ERK pathway activation in childhood acute lymphoblastic leukemia and its therapeutic targeting. Front Oncol. 2014;4:160. doi:10.3389/fonc.2014.00160.PubMedCentralPubMedCrossRef

81.

Packer LM, Rana S, Hayward R, O’Hare T, Eide CA, Rebocho A, et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell. 2011;20(6):715–27. doi:10.1016/j.ccr.2011.11.004.PubMedCentralPubMedCrossRef

82.

Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, Hofmann WK, et al. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med. 2004;199(5):673–85. doi:10.1084/jem.20031637.PubMedCentralPubMedCrossRef

83.

Maino E, Sancetta R, Viero P, Imbergamo S, Scattolin AM, Vespignani M, et al. Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther. 2014;14(6):723–40. doi:10.1586/14737140.2014.895669.PubMedCrossRef

84.

Tanimura A, Yujiri T, Tanaka Y, Hatanaka M, Mitani N, Nakamura Y, et al. The anti-apoptotic role of the unfolded protein response in Bcr-Abl-positive leukemia cells. Leuk Res. 2009;33(7):924–8. doi:10.1016/j.leukres.2009.01.027.PubMedCrossRef

85.

Dengler MA, Staiger AM, Gutekunst M, Hofmann U, Doszczak M, Scheurich P, et al. Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis. PLoS One. 2011;6(9):e25139. doi:10.1371/journal.pone.0025139.PubMedCentralPubMedCrossRef

86.

Li Y, Guo Y, Tang J, Jiang J, Chen Z. New insights into the roles of CHOP-induced apoptosis in ER stress. Acta Biochim Biophys Sin. 2014;46(8):629–40. doi:10.1093/abbs/gmu048.PubMedCrossRef

87.

Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, et al. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2014;111(21):E2219–28. doi:10.1073/pnas.1400958111.PubMedCentralPubMedCrossRef

88.

Swaminathan S, Huang C, Geng H, Chen Z, Harvey R, Kang H, et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat Med. 2013;19(8):1014–22. doi:10.1038/nm.3247.PubMedCentralPubMedCrossRef

89.

Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph(+)ALL—role of ponatinib. Biologics. 2014;8:243–54. doi:10.2147/BTT.S50734.PubMedCentralPubMed

90.

Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol. 2009;27(31):5175–81. doi:10.1200/JCO.2008.21.2514.PubMedCentralPubMedCrossRef

91.

Laurenti E, Doulatov S, Zandi S, Plumb I, Chen J, April C, et al. The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. Nat Immunol. 2013;14(7):756–63. doi:10.1038/ni.2615.PubMedCrossRef

92.

van Galen P, Kreso A, Mbong N, Kent DG, Fitzmaurice T, Chambers JE, et al. The unfolded protein response governs integrity of the haematopoietic stem-cell pool during stress. Nature. 2014;510(7504):268–72. doi:10.1038/nature13228.PubMedCrossRef

93.

Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105–11. doi:10.1038/35102167.PubMedCrossRef

94.

Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 2005;15(9):494–501. doi:10.1016/j.tcb.2005.07.004.PubMedCrossRef

95.

Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101(12):4701–7. doi:10.1182/blood-2002-09-2780.PubMedCrossRef

96.

Holtz M, Forman SJ, Bhatia R. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res. 2007;67(3):1113–20. doi:10.1158/0008-5472.CAN-06-2014.PubMedCrossRef

97.

Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013;73(6):1993–2002. doi:10.1158/0008-5472.CAN-12-3109.PubMedCrossRef

98.

Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012;55(16):7193–207. doi:10.1021/jm300713s.PubMedCrossRef

99.

Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011;117(4):1311–4. doi:10.1182/blood-2010-08-303099.PubMedCentralPubMedCrossRef

100.

Volkmann K, Lucas JL, Vuga D, Wang X, Brumm D, Stiles C, et al. Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease. J Biol Chem. 2011;286(14):12743–55. doi:10.1074/jbc.M110.199737.PubMedCentralPubMedCrossRef

101.

Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood. 2012;119(24):5772–81. doi:10.1182/blood-2011-07-366633.PubMedCentralPubMedCrossRef

102.

Cross BC, Bond PJ, Sadowski PG, Jha BK, Zak J, Goodman JM, et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc Natl Acad Sci U S A. 2012;109(15):E869–78. doi:10.1073/pnas.1115623109.PubMedCentralPubMedCrossRef

103.

Tsai YC, Weissman AM. The unfolded protein response, degradation from endoplasmic reticulum and cancer. Genes Cancer. 2010;1(7):764–78. doi:10.1177/1947601910383011.PubMedCentralPubMedCrossRef

104.

Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015;125(20):3076–84. doi:10.1182/blood-2014-09-568915.PubMedCrossRef

105.

Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat. 2015;18:18–35. doi:10.1016/j.drup.2014.12.001.PubMedCrossRef

106.

Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 2008;112(6):2489–99. doi:10.1182/blood-2007-08-104950.PubMedCrossRef

107.

Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol. 1998;143(7):1883–98.PubMedCentralPubMedCrossRef

108.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24(3):289–304. doi:10.1016/j.ccr.2013.08.009.PubMedCentralPubMedCrossRef

109.

Kusio-Kobialka M. Pro-survival signaling pathways activated by BCR-ABL oncogene in chronic myelogenous leukemia cells: the role of the perk-EIF2alpha signal path and acetylation of p53. Postepy Biochem. 2014;60(4):401–6.PubMed

110.

Ermakova SP, Kang BS, Choi BY, Choi HS, Schuster TF, Ma WY, et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006;66(18):9260–9. doi:10.1158/0008-5472.CAN-06-1586.PubMedCrossRef

111.

Uckun FM, Qazi S, Ozer Z, Garner AL, Pitt J, Ma H, et al. Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br J Haematol. 2011;153(6):741–52. doi:10.1111/j.1365-2141.2011.08671.x.PubMedCrossRef

112.

Liu Y, Steiniger SC, Kim Y, Kaufmann GF, Felding-Habermann B, Janda KD. Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Mol Pharm. 2007;4(3):435–47. doi:10.1021/mp060122j.PubMedCentralPubMedCrossRef

113.

Rosenes Z, Mulhern TD, Hatters DM, Ilag LL, Power BE, Hosking C, et al. The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78. PLoS One. 2012;7(9):e44927. doi:10.1371/journal.pone.0044927.PubMedCentralPubMedCrossRef

114.

Rasche L, Duell J, Morgner C, Chatterjee M, Hensel F, Rosenwald A, et al. The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78. PLoS One. 2013;8(5):e63414. doi:10.1371/journal.pone.0063414.PubMedCentralPubMedCrossRef

115.

Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, et al. GRP78-directed immunotherapy in relapsed or refractory multiple myeloma—results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6. Haematologica. 2015;100(3):377–84. doi:10.3324/haematol.2014.117945.PubMedCentralPubMedCrossRef

116.

Kriss CL, Pinilla-Ibarz JA, Mailloux AW, Powers JJ, Tang CH, Kang CW, et al. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood. 2012;120(5):1027–38. doi:10.1182/blood-2011-11-394346.PubMedCentralPubMedCrossRef

117.

Carlini L, Manley S. Live intracellular super-resolution imaging using site-specific stains. ACS Chem Biol. 2013;8(12):2643–8. doi:10.1021/cb400467x.PubMedCrossRef

118.

Sanches M, Duffy NM, Talukdar M, Thevakumaran N, Chiovitti D, Canny MD, et al. Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors. Nat Commun. 2014;5:4202. doi:10.1038/ncomms5202.PubMedCentralPubMedCrossRef

119.

Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70. doi:10.1186/s13045-014-0070-8.PubMedCentralPubMedCrossRef

120.

Hollien J, Lin JH, Li H, Stevens N, Walter P, Weissman JS. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol. 2009;186(3):323–31. doi:10.1083/jcb.200903014.PubMedCentralPubMedCrossRef

121.

Tam AB, Koong AC, Niwa M. Ire1 has distinct catalytic mechanisms for XBP1/HAC1 splicing and RIDD. Cell Rep. 2014;9(3):850–8. doi:10.1016/j.celrep.2014.09.016.PubMedCentralPubMedCrossRef

122.

Wang FM, Galson DL, Roodman GD, Ouyang H. Resveratrol triggers the pro-apoptotic endoplasmic reticulum stress response and represses pro-survival XBP1 signaling in human multiple myeloma cells. Exp Hematol. 2011;39(10):999–1006. doi:10.1016/j.exphem.2011.06.007.PubMedCentralPubMedCrossRef

Title: Drugging the unfolded protein response in acute leukemias
Authors: Behzad Kharabi Masouleh
Eric Chevet
Jens Panse
Edgar Jost
Michael O’Dwyer
Tim H. Bruemmendorf
Afshin Samali
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2015
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-015-0184-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Aloperine executes antitumor effects against multiple myeloma through dual apoptotic mechanisms

Alteration of gene expression profile following PPP2R5C knockdown may be associated with proliferation suppression and increased apoptosis of K562 cells

Transfer of microRNAs by extracellular membrane microvesicles: a nascent crosstalk model in tumor pathogenesis, especially tumor cell-microenvironment interactions

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer